Psychedelic Research

Psychedelic Research Literature Reviews

We're updating and moving some things around. Your browser may show security errors or the formatting of the pages you see here may be outdated. Feel free to have a look around-- this is all hand-curated, but our most updated information can be found through our main page https://psychedelicmentalhealth.net/about where you can learn about membership options for the general public as well as for psychedelic clinicians interested in professional development in psychedelic mental health.

content-fit " style="position: relative;overflow: hidden">

 

Ketamine Research

Therapeutic ketamine research has continued non-stop since 1962, and has been safely administered to billions of people around the world since it was approved by the FDA in 1970 for use in humans and animals.

https://toad.social/@PsychedelicInstitute

Psychedelic Research Mastodon

Mastodon on the Fediverse for bite-syzed psychedelic news and research headlines

 

https://lemmy.world/u/PlanetMedicines

Lemmy

Psychedelic Communities Lemmy

Lemmy on the Fediverse for community-oriented discussion on psychedelic news and research


Jun 7, 2024 Psychotherapist Tammy Nelson Discusses Couples Therapy and Ketamine— A New Way to Enrich Relationships

Jun 4, 2024 Psychedelics in Palliative Care, Ready for Primetime! Making the Case for Ketamine-Assisted Psychotherapy (Horowitz, et al, 2024)


Jun 4, 2024

Preliminary evidence demonstrates that Ketamine-Assisted Psychotherapy (KAP) can significantly improve depression, demoralization and existential distress in seriously ill people. We will discuss: 1. the history and science of psychedelics; 2. ketamine pharmacology, and KAP indications and delivery models; 3. putative KAP mechanisms of action; and 4. examples of KAP program development, including making the case, potential obstacles, and creative solutions.


Apr 24, 2024 Ketamine in Bipolar Disorder: A Review (Wilkowska, et al, 2020)


Apr 20, 2024 A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review (Wong, et al, 2024)


Apr 20, 2024

Relatively few pharmacologic agents are proven safe and effective in adults with TRD. NNT estimates for investigational psilocybin and esketamine in TRD indicate clinical meaningfulness. The NNH profile for both aforementioned agents is clinically acceptable. Our results underscore the clinical relevance of these treatment options in adults with TRD.




Apr 20, 2024 Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis (Kwan, et al, 2024)


Apr 20, 2024

A low number to treat and a high number to harm suggests efficacy and safety of racemic ketamine and esketamine across thousands of clients. It takes not very many ketamine treatments to help, and a large number of treatments to statiscally help and harm, also indicating a range of safe repeated dosing.


Apr 20, 2024


Mar 26, 2024 Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial w/ open-label extension (Apeldoorn et al, 2024) adds to previous ketamine findings




Mar 26, 2024

Deep posteromedial cortical rhythm in dissociation (2020)


Sep 28, 2023 Deep posteromedial cortical rhythm in dissociation (2020)


Sep 28, 2023

Dissociation in human beings is a self-reported state of mind, and no experimental technique in rodents or in humans can currently define this subjective experience in full. However, the clinically guided paradigm reported here could provide a framework of behavioural, optical and physiological tools to enable exploration of the neural activity that underlies dissociative states (Vesuna, et al, 2019).


Sep 28, 2023

Ketamine in neuropsychiatric disorders: an update (Johnston, et al, 2023)


Sep 19, 2023 Ketamine in neuropsychiatric disorders: an update (Johnston, et al, 2023)


Sep 19, 2023

Considerable clinical research supports the use of—or further research with—subanesthetic-dose ketamine and its (S)-enantiomer esketamine in multiple neuropsychiatric disorders including depression, bipolar disorder, anxiety spectrum disorders, substance use disorders, and eating disorders, as well as for the management of chronic pain.


Sep 19, 2023

Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’


Sep 17, 2023 Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’


Sep 17, 2023

Significant differences between those scoring high and low (on psychedelic preparedness) before the psychedelic experience were found on measures of mental health/wellbeing outcomes assessed after the experience, suggesting that the scale has predictive utility.


Sep 17, 2023

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology (2023)


Mar 21, 2023 Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology (2023)


Mar 21, 2023

While the neural underpinnings remain to be clarified, the psychedelic-induced state seems to allow one to recollect and process deep autobiographical information, achieve new understandings of one's self and relationships with others, and gain greater appreciation of one's place within the cosmos.5,61,62 This state is closely linked to the concept of “mystical experience” which in multiple studies with classic psychedelics predicts therapeutic efficacy.9,11,45,47,55 “Ego dissolution” is another term used to describe a loss of the usual sense of self as separate entity.13 The quality and degree of psychedelic-induced ego dissolution and mystical experience are typically measured in clinical trials with validated psychometric instruments such as the 5-Dimensional Altered States of Consciousness Questionnaire and the Mystical Experience Questionnaire.9,11,45,47,49,55,61


Mar 21, 2023

The NMDA receptor antagonists memantine and ketamine as anti-migraine agents (Podkawa, et al, 2023)


Mar 6, 2023 The NMDA receptor antagonists memantine and ketamine as anti-migraine agents (Podkawa, et al, 2023)


Mar 6, 2023

Migraine is a debilitating disorder affecting females more frequently than males. There is some evidence that drugs targeting glutamate receptors: memantine and ketamine might be beneficial in the therapy of this entity. Therefore, the purpose of this work is to present NMDA receptor antagonists, memantine and ketamine, as potential anti-migraine agents.


Mar 6, 2023

Ketamine and the conscious mind (1972)


Mar 4, 2023 Ketamine and the conscious mind (1972)


Mar 4, 2023

It is a matter of opinion whether or not a chemically induced transcendental experience should be available to anyone who desires it, but to induce such a state when it is not requested by the patient is a different ethical problem.


Mar 4, 2023

A pilot randomized controlled trial of ketamine in Borderline Personality Disorder (2023)


Feb 17, 2023 A pilot randomized controlled trial of ketamine in Borderline Personality Disorder (2023)


Feb 17, 2023

Infusions were well tolerated in both groups. Dissociative symptoms during infusion were more intense with ketamine than midazolam (t(12.3) = 3.61, p = 0.01), but they resolved by 40 min after infusion in both groups. Post-infusion adverse events were at the expected low levels in both groups.


Feb 17, 2023

Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis (Philipp-Muller, et al, 2023)


Feb 11, 2023 Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis (Philipp-Muller, et al, 2023)


Feb 11, 2023

Pharmacologically enhanced psychotherapy is one potential means of prolonging ketamine’s effects, with the class of psychedelic medications (in which ketamine is included) yielding encouraging results

Mastodon Mastodon